1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)-2-(4-methoxyphenyl)ethan-1-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)-2-(4-methoxyphenyl)ethan-1-one
• 英文别名: 1-(5-Methoxy-2,2-dimethylchromen-6-yl)-2-(4-methoxyphenyl)ethanone；1-(5-methoxy-2,2-dimethylchromen-6-yl)-2-(4-methoxyphenyl)ethanone
• 化学式: C₂₁H₂₂O₄
• 分子量: 338.403
• InChiKey: VASGUBTWBKZATA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  对甲氧基苯乙醇 在 正丁基锂 、 碳酸氢钠 、 戴斯-马丁氧化剂 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 3.5h， 生成 1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)-2-(4-methoxyphenyl)ethan-1-one
  参考文献：
  名称：

  Novel Hypoxia-Inducible Factor 1α (HIF-1α) Inhibitors for Angiogenesis-Related Ocular Diseases: Discovery of a Novel Scaffold via Ring-Truncation Strategy

  摘要：

  Ocular diseases featuring pathologic neovascularization are the leading cause of blindness, and anti-VEGF agents have been conventionally used to treat these diseases. Recently, regulating factors upstream of VEGF, such as HIF-1 alpha, have emerged as a desirable therapeutic approach because the use of anti-VEGF agents is currently being reconsidered due to the VEGF action as a trophic factor. Here, we report a novel scaffold discovered through the complete structure-activity relationship of ring-truncated deguelin analogs in HIF-1 alpha inhibition. Interestingly, analog 6i possessing a 2-fluorobenzene moiety instead of a dimethoxybenzene moiety exhibited excellent HIF-1 alpha inhibitory activity, with an IC50 value of 100 nM. In particular, the further ring-truncated analog 34f, which showed enhanced HIF-la inhibitory activity compared to analog 2 previously reported by us, inhibited in vitro angiogenesis and effectively suppressed hypoxia-mediated retinal neovascularization. Importantly, the heteroatom-substituted benzene ring as a key structural feature of analog 34f was identified as a novel scaffold for HIF-1 alpha inhibitors that can be used in lieu of a chromene ring.

  DOI：

  10.1021/acs.jmedchem.8b00971

文献信息

• Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors
  作者：Hong Yao、Feijie Xu、Guangyu Wang、Shaowen Xie、Wenlong Li、Hequan Yao、Cong Ma、Zheying Zhu、Jinyi Xu、Shengtao Xu

  DOI：10.1016/j.ejmech.2019.02.014

  日期：2019.4

  A series of novel B and C-rings truncated deguelin derivatives have been designed and synthesized in the present study as heat shock protein 90 (Hsp90) inhibitors. The synthesized compounds exhibited micromolar antiproliferative potency toward a panel of human cancer cell lines. Their structure-activity relationships (SARs) were investigated in a systematic manner. Compound 21c was identified to have

  在本研究中，已经设计并合成了一系列新颖的B和C环截短的deguelin衍生物，作为热激蛋白90（Hsp90）抑制剂。合成的化合物对一组人类癌细胞系表现出微摩尔的抗增殖能力。以系统的方式研究了它们的构效关系（SAR）。鉴定出化合物21c具有高的Hsp90结合能力（60nM），并通过遍在蛋白蛋白酶体系统引起客户蛋白降解。进一步的生物学研究表明，化合物21c诱导了人乳腺癌MCF-7细胞的剂量依赖性S和G2期细胞周期停滞。流式细胞仪和蛋白质印迹分析证实了化合物21c导致MCF-7细胞凋亡。另外，化合物21c对MCF-7细胞的迁移和侵袭表现出很强的抑制作用。综上所述，这些结果表明21c可能是Hsp90抑制剂进一步开发的有前途的先导化合物。
• NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：SNU R&DB FOUNDATION

  公开号：US20160340331A1

  公开（公告）日：2016-11-24

  A compound inhibiting Hsp90 and a pharmaceutical composition including the same as an active ingredient are described, which compound is represented by formula 2 and suppresses the expression of Hsp90, inhibits the accumulation of HIF-1α, the Hsp90 client protein, and efficiently inhibits the activation of VEGF. The compound displays low cytotoxicity and can be effectively used as an active ingredient of an anti-cancer agent, a diabetic retinopathy treating agent, and an anti-arthritic agent.
• US9745280B2
  申请人：——

  公开号：US9745280B2

  公开（公告）日：2017-08-29